Ars2‐containing bispecific, Fab‐ and IgG1‐format BAR‐bodies to target DLBCL cells

Despite recent advances in the therapy of diffuse large B‐cell lymphoma, not otherwise specified (DLBCL), around 30% of patients develop refractory disease or relapse after first‐line treatment. Recently, Ars2 was reported as the auto‐antigenic target of the B‐cell receptor (BCR) in approximately 25...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiefer, Maximilian, Thurner, Lorenz, Bock, Theresa, Cetin, Onur, Kos, Igor, Lesan, Vadim, Kaddu‐Mulindwa, Dominic, Bittenbring, Joerg Thomas, Fadle, Natalie, Regitz, Evi, Hoth, Markus, Neumann, Frank, Preuss, Klaus‐Dieter, Pfreundschuh, Michael, Christofyllakis, Konstantinos, Bewarder, Moritz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Haematologic Malignancy ‐ Lymphoid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928785/
https://www.ncbi.nlm.nih.gov/pubmed/36819155
http://dx.doi.org/10.1002/jha2.635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928785/
https://www.ncbi.nlm.nih.gov/pubmed/36819155
http://dx.doi.org/10.1002/jha2.635

Ejemplares similares